Keynote Luncheon Address by James Cornelius, CEO of Bristol-Myers Squibb
BASKING RIDGE, N.J., Oct. 19 /PRNewswire-FirstCall/ -- VioQuest Pharmaceuticals (OTC Bulletin Board: VQPH) today announced that Daniel Greenleaf, President and Chief Executive Officer of VioQuest Pharmaceuticals, will be presenting at the Paramount BioSciences Healthcare Conference on Tuesday, October 23, at 10:45 a.m. EDT at the Waldorf Astoria Hotel in New York City. Mr. Greenleaf will provide a company overview and update on the status of VioQuest's current clinical development programs.
Those who are interested in attending may visit http://www.paramountbio.com/hcare2007 to register. Or, contact Ms. Tara Crosson of Paramount BioSciences at email@example.com or (212) 554-4351.
About VioQuest Pharmaceuticals
VioQuest focuses on acquiring, developing, and commercializing targeted
late preclinical and early clinical stage therapies with unique mechanisms
of action primarily for oncology and infectious diseases. VioQuest has
three targeted drug candidates in clinical development: VQD-002 which
inhibits activation of Akt that is seen at abnormally high levels in
breast, ovarian, colorectal, pancreatic, and hematologic cancers;
Lenocta(TM), an inhibitor of specific protein tyrosine phosphatases
(PTPases), SHP-1 and SHP-2, which has shown compelling clinical and
biological activity in solid tumors and Xyfid(TM), a topical therapy which
has shown early clinical promise in the treatment and prevention of
chemo-induced Hand-Foot Syndrome (HFS). VioQuest anticipates commencing
several Phase II trials for VQD-002, Lenocta(TM) and Xyfid(TM) in the
second half of 2007. In addition, VioQuest and the U.S. Army are planning
to submit a New Drug Application (NDA) to the U. S. Food and Drug
Administration (FDA) in 2007 for Lenocta(TM) for the treatment of
|SOURCE VioQuest Pharmaceuticals|
Copyright©2007 PR Newswire.
All rights reserved